2026
Expert Panel Expresses Clear Support for Urine-Based Biomarkers in Hematuria Evaluation
Pacific Edge today summarizes the opinions expressed by the panel of experts during the Contractor Advisory Committee (CAC) meeting organized by Novitas on Thursday 19 February 2026 (US time) regarding the use of urine-based biomarker tests in the evaluation of hematuria. [read more]
Medicare Contractor Novitas Schedules Expert Panel
Pacific Edge notes its Medicare Administrative Contractor (MAC) Novitas has confirmed the scheduling of its planned Contractor Advisory Committee (CAC) to consider the evidence for urine biomarkers in patients with hematuria. [read more]
Kaiser Study Backs Triage Ahead of Medicare Panel
Pacific Edge welcomes the publication, in the journal 'Urology Practice', of a Kaiser Permanente study demonstrating the real-world Clinical Utility of Cxbladder Triage in the largest ever urine-based biomarker study on patients presenting with hematuria. [read more]
Q3 26 Results and Key Strategic Milestones
Pacific Edge releases its Investor Update for the three months to the end of December 2025 (Q3 26) today with reports on further strategic achievements to support a reinstatement of Medicare coverage of Cxbladder and the volume of Cxbladder tests processed through its laboratories. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.
